Región Metropolitana de Santiago
Este organismo compró $35.329.096.472 en 11.633 órdenes de compra , sobre todo en Medicamentos y productos farmacéuticos / Medicamentos anti infecciosos / Medicamentos antivirales y le compró principalmente a Sur Medical SpA.
238 meses con data · color por monto (sqrt scale)
| Año | Ene | Feb | Mar | Abr | May | Jun | Jul | Ago | Sep | Oct | Nov | Dic | Total año |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
| $1367,1 M |
| 2025 | $2402,7 M |
| 2024 | $2107,2 M |
| 2023 | $2816,8 M |
| 2022 | $1338 M |
| 2021 | $1018,6 M |
| 2020 | $888,8 M |
| 2019 | $901,2 M |
| 2018 | $1471,2 M |
| 2017 | $786,1 M |
| 2016 | $14,2 mil M |
| 2015 | $919,8 M |
| 2014 | $428,8 M |
| 2013 | $340,8 M |
| 2012 | $359,5 M |
| 2011 | $701,4 M |
| 2010 | $913,7 M |
| 2009 | $590,7 M |
| 2008 | $571,8 M |
| 2007 | $1180,7 M |
| 2006 | $34,7 M |
238 períodos con data
Fuente: Agregaciones mensuales sobre OCs ingeridas
10 contrapartes
Fuente: Tabla top_contrapartes_comprador
| Código | Fecha | Proveedor | Estado | Monto |
|---|---|---|---|---|
| 2980-405-AG24 | 26-12-2024 | Bayer S.A. | Recepcion Conforme | $5.051.932 |
| 2980-406-AG24 | 26-12-2024 | Gador Limitada | Aceptada | $3.094.000 |
| 2980-407-AG24 | 26-12-2024 | Glaxosmithkline Chile Farmaceutica Limitada | Aceptada | $3.427.200 |
| 2980-408-AG24 | 26-12-2024 | Novofarma Service S.A. | Aceptada | $5.297.980 |
| 2980-409-AG24 | 26-12-2024 | Astrazeneca S.A. | Recepcion Conforme | $5.865.510 |
| 2980-410-SE24 | 26-12-2024 | Laboratorios Andromaco S.A. | Recepcion Conforme | $6.466.163 |
| 2980-411-SE24 | 26-12-2024 | Novartis Chile S.A. | Recepcion Conforme | $5.395.291 |
| 2980-412-SE24 | 26-12-2024 | Johnson y Johnson de Chile S.A. | Recepcion Conforme | $5.002.427 |
| 2980-413-SE24 | 26-12-2024 | Abbvie Productos Farmaceuticos Limitada | Recepcion Conforme | $4.748.100 |
| 2980-414-SE24 | 26-12-2024 | Laboratorios Andromaco S.A. | Recepcion Conforme | $2.586.465 |
| 2980-358-SE24 | 20-12-2024 | Johnson y Johnson de Chile S.A. | Recepcion Conforme | $33.349.512 |
| 2980-393-AG24 | 20-12-2024 | Novartis Chile S.A. | Recepcion Conforme | $5.895.474 |
| 2980-394-AG24 | 20-12-2024 | Novartis Chile S.A. | Recepcion Conforme | $2.781.487 |
| 2980-395-AG24 | 20-12-2024 | Novartis Chile S.A. | Recepcion Conforme | $5.395.291 |
| 2980-396-AG24 | 20-12-2024 | Novartis Chile S.A. | Recepcion Conforme | $4.287.979 |
| 2980-397-AG24 | 20-12-2024 | Glaxosmithkline Chile Farmaceutica Limitada | Aceptada | $3.123.036 |
| 2980-398-AG24 | 20-12-2024 | Astrazeneca S.A. | Recepcion Conforme | $5.865.510 |
| 2980-399-AG24 | 20-12-2024 | Synthon Chile Limitada | Recepcion Conforme | $5.947.204 |
| 2980-400-AG24 | 20-12-2024 | Gador Limitada | Aceptada | $2.624.593 |
| 2980-401-AG24 | 20-12-2024 | Fresenius Kabi Chile Limitada | Recepcion Conforme | $410.550 |
| 2980-402-AG24 | 20-12-2024 | Novartis Chile S.A. | Recepcion Conforme | $3.214.071 |
| 2980-403-SE24 | 20-12-2024 | Gador Limitada | Recepcion Conforme | $3.094.000 |
| 2980-404-SE24 | 20-12-2024 | Bayer S.A. | Aceptada | $5.051.932 |
| 2980-392-SE24 | 18-12-2024 | Productos Farmoquimicos Roche Limitada | Recepcion Conforme | $3.020.125 |
| 2980-391-SE24 | 16-12-2024 | Novartis Chile S.A. | Recepcion Conforme | $5.355.036 |
| 2980-383-AG24 | 13-12-2024 | Synthon Chile Limitada | Recepcion Conforme | $1.139.544 |
| 2980-384-AG24 | 13-12-2024 | Novartis Chile S.A. | Recepcion Conforme | $799.813 |
| 2980-385-AG24 | 13-12-2024 | Emcure Pharma Chile SpA | Recepcion Conforme | $121.618 |
| 2980-386-AG24 | 13-12-2024 | Glaxosmithkline Chile Farmaceutica Limitada | Recepcion Conforme | $738.255 |
| 2980-380-AG24 | 10-12-2024 | Inversiones Tecnologicas S.A. | Recepcion Conforme | $799.656 |
